Content about Diclofenac

March 4, 2013
FDA accepts application for NSAID painkiller

The Food and Drug Administration has accepted a regulatory application for a new painkiller from Iroko Pharmaceuticals, the drug maker said.

PHILADELPHIA — The Food and Drug Administration has accepted a regulatory application for a new painkiller from Iroko Pharmaceuticals, the drug maker said Monday.

Iroko is seeking approval for a lower-dose, submicron diclofenac, a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain in adults.

January 7, 2013
Harvard Men's Health Watch recommends topical analgesics for acute joint pain

Topical pain relievers may be better suited for joint pain, according to a report published in the January 2013 issue of the Harvard Men's Health Watch.

BOSTON — Topical pain relievers may be better suited for joint pain, according to a report published in the January 2013 issue of the Harvard Men's Health Watch. 

"Topical pain relievers can be very helpful for the more superficial joints like the knees, ankles, feet, elbows and hands," stated Rosalyn Nguyen, a clinical instructor in physical medicine and rehabilitation at Harvard Medical School. "In those areas, the medication can penetrate closer to the joint."

July 12, 2012
FDA approves Watson arthritis drug

The Food and Drug Administration has approved a generic drug for arthritis made by Watson Pharmaceuticals, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for arthritis made by Watson Pharmaceuticals, the company said.

Watson announced that the FDA approved a subsidiary's application for diclofenac sodium and misoprostol delayed-release tablets. The drug is a generic version of G.D. Searle's Arthrotec, used to treat osteoarthritis and rheumatoid arthritis in patients who have high risk of developing ulcers related to the use of non-steroidal anti-inflammatory drugs, or NSAIDs, a class that includes the painkiller ibuprofen.

June 16, 2010
Study: Celebrex less likely to cause GI issues than other NSAIDs

Arthritis patients at risk of harmful gastrointestinal side effects due to use of a class...

June 7, 2010
Nautilus launches Cambia

Nautilus Neurosciences has launched a new treatment for migraines, the drug maker said Tuesday....

February 22, 2010
Endo reports 2009 profits

Endo Pharmaceuticals saw profits of $334.3 million in 2009, a 9% increase over 2008’s $305.7...